Hims & Hers Health, Inc. $HIMS Stock Holdings Lessened by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 0.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 97,503 shares of the company’s stock after selling 899 shares during the period. Mutual of America Capital Management LLC’s holdings in Hims & Hers Health were worth $4,861,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HIMS. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 128.5% during the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company’s stock valued at $152,000 after purchasing an additional 2,892 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Hims & Hers Health by 42.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 12,588 shares of the company’s stock valued at $372,000 after purchasing an additional 3,770 shares during the period. Janney Montgomery Scott LLC bought a new position in Hims & Hers Health during the 1st quarter worth $257,000. Blue Trust Inc. increased its position in Hims & Hers Health by 119.8% in the first quarter. Blue Trust Inc. now owns 1,923 shares of the company’s stock worth $57,000 after buying an additional 1,048 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its stake in Hims & Hers Health by 8.5% in the first quarter. Oppenheimer & Co. Inc. now owns 39,289 shares of the company’s stock valued at $1,161,000 after buying an additional 3,079 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $54.38, for a total value of $143,400.06. Following the transaction, the insider owned 161,130 shares of the company’s stock, valued at approximately $8,762,249.40. This represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $8,581,970. This represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,432,206 shares of company stock valued at $74,248,448 over the last quarter. Company insiders own 13.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on HIMS. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Truist Financial decreased their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. KeyCorp initiated coverage on Hims & Hers Health in a report on Tuesday. They set a “sector weight” rating on the stock. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Price Performance

NYSE HIMS opened at $47.45 on Thursday. Hims & Hers Health, Inc. has a 12 month low of $18.33 and a 12 month high of $72.98. The firm has a market capitalization of $10.72 billion, a PE ratio of 59.31, a P/E/G ratio of 3.42 and a beta of 2.25. The company’s 50 day simple moving average is $51.05 and its 200 day simple moving average is $49.20. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period in the previous year, the business posted $0.06 earnings per share. The business’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.